4TECH | Transcatheter Solutions for Tricuspid Valve Disease

News Release

FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates, Inc., +1 508-359-4005, x108

4Tech and Dr. Jean-Claude Laborde enter into partnership to accelerate 4Tech R&D and clinical development

"Dr. Laborde has had a seminal influence on how cardiologists practice interventional medicine around the world. We are privileged to have him collaborating with 4Tech, which strengthens our position as the leader in transcatheter solutions to treat Tricuspid Valve disease."
Carine Schorochoff, CEO, 4Tech Inc.

GALWAY, Ireland, May 16, 2016—**4Tech Inc.**, which is developing the world's first transcatheter device, **TriCinch™**, for repair of the Tricuspid heart valve, today announced its partnership with **Dr. Jean-Claude Laborde** as an R&D and clinical advisor focused on fast-forwarding the TriCinch™ Generation Two and Generation Three programs.

Dr. Laborde is an internationally recognized cardiologist and one of the world leaders in transcatheter aortic valve implantation (TAVI). He holds numerous patents for novel medical devices that have changed how cardiologists practice medicine and has designed new medical procedures to treat specific cardiac conditions. Dr. Laborde is a Key Opinion Leader (KOL) in interventional cardiology, having spoken around the world about TAVI and other new medical procedures and trained hundreds of physicians internationally.

"Tricuspid Regurgitation represents a significant unmet clinical need," said Dr. Laborde, who previously supported the development of **CoreValve** when it was emerging, which he helped transform into a successful medical device business, serving as Chief Medical Officer until CoreValve was purchased by Medtronic in 2009. "4Tech is the sole company that is 100-percent-focused on repairing the Tricuspid Valve and possesses in-depth knowledge of the Tricuspid Valve anatomy and pathology. I am very proud to be a part of 4Tech."

"We look forward to our partnership with Dr. Laborde, whom we expect will greatly assist 4Tech in accelerating our R&D and clinical programs," said **Carine Schorochoff**, Co-Founder and CEO of 4Tech.

Dr. Laborde continues to provide proctoring support for TAVI devices. In addition, he has also been involved in training and teaching cardiologists and interventional cardiologists how to use TAVI devices, how to properly select patients and establish safe and effective protocols for hospitals and clinics. Dr. Laborde was intimately involved in the development of the Transcatheter Mitral Valve Replacement solution developed by **CardiAQ**, which was acquired by Edwards Lifesciences in 2015.

Recent News Releases:
April 7, 2016—4Tech appoints Paul Cornelison as Global VP of Reg. Affairs, QA and Clinical Affairs

March 16, 2016—4Tech appoints Hardip Thakerar as Global Vice President of Therapy Development
March 9, 2016—4Tech Completes $29 Million Series B Round of Financing

About 4Tech Inc.
4Tech Inc. (www.4techtricuspid.com) is incorporated in Delaware, USA, with operations in Galway, Ireland (4Tech Cardio Ltd). 4Tech has developed a proprietary transcatheter solution for the treatment of TR. Because of its unique anchoring and tensioning mechanism, the 4Tech **#TriCinch** System for Transcatheter Tricuspid Valve Repair allows a simple and reproducible percutaneous procedure, designed to reduce TR and restore patient quality of life, while also allowing substantial potential cost-savings for the healthcare systems.

Caution: The 4Tech TriCinch™ System for Transcatheter Tricuspid Valve Repair is in the early phase of development. It will not be available in the USA for clinical trials until further notice and is NOT available for sale.

Caution: This news release contains certain "forward-looking" statements under the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of 4Tech are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, the FDA's approval of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.

# # #